Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.
Meletios A. Dimopoulos, MD
Results from the phase III iNNOVATE (PCYC-1127) trial established the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) as the new standard of care in Waldenström macroglobulinemia, said Meletios A. Dimopoulos, MD.
Dimopoulos, professor and chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine in Athens, Greece, presented the results at the 2018 ASCO Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine.1,2
The combination reduced the risk for disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia. At a median follow-up of 26.5 months, the median progression-free survival (PFS) per independent review was not reached with the ibrutinib combination and was 20.3 months with rituximab alone (HR, 0.20; 95% CI, 0.11-0.38, P <.0001). The 30-month PFS rates were 82% versus 28%, respectively.
Investigators recruited 150 relapsed/refractory or treatment-naïve patients with confirmed symptomatic Waldenström macroglobulinemia into the double-blind, placebo-controlled, parallel assignment, randomized trial. Patients enrolled at 45 sites in 9 countries from July 2014 to January 2016.
Patients received intravenous rituximab at 375 mg/m2 once weekly for 4 straight weeks, followed by another 4-week rituximab course after a 3-month interval. Ibrutinib at 420 mg or placebo were taken once daily continuously. PFS was the primary endpoint, with secondary endpoints including overall response rate (ORR), hematological improvement measured by hemoglobin, time to next treatment, overall survival (OS), and safety.
Based on these findings, the FDA granted a priority review designation in June 2018 to a supplemental new drug application for use of ibrutinib (Imbruvica) in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
“With the combination of ibrutinib and rituximab, we were able to abrogate the adverse effect of these mutations,” he said. “We believe now that we have a new standard of care for the treatment of this disease and, in the future, we would like to have further improvements. We would like to increase the depths of response; we only had a minority of patients who achieved very good partial response or complete response.”
In an interview with OncLive, Dimopoulos discussed what he hopes to see in the final analysis of iNNOVATE and the development of future treatments for Waldenström macroglobulinemia.Dimopoulos: Waldenström macroglobulinemia is an unusual, low-grade lymphoplasmacytic lymphoma. Among active treatments for this disease, we have the anti-CD20 monoclonal antibody rituximab, which has been around for 25 years. It is one of the most frequent therapies given as a single agent. Among other agents, we have nucleoside analogues, we have proteasome inhibitors, and in the past few years, there has been a significant interest for treating this disease with BTK inhibitors. The first one was ibrutinib.
Two phase II studies have shown that single-agent ibrutinib is associated with responses in the majority of patients, which appear to be durable. As we know, ibrutinib is given orally on a daily basis without discontinuation.
In the iNNOVATE trial, we wanted to perform a prospective, placebo-controlled, randomized trial—this is a difficult task, because Waldenström’s macroglobulinemia is a rare disease—which would compare the standard of care, which is rituximab, with placebo versus rituximab with ibrutinib. In both arms, patients received rituximab. In one arm, they received placebo. In the other arm, they received ibrutinib [with rituximab].
The primary endpoint of the study was PFS, with secondary endpoints being OS, ORR, safety, and tolerability.At the time of the first interim analysis, we observed a highly significant, statistically very important difference in favor of the investigational arm, with a hazard ratio [per investigator assessment] of 0.22. With a median follow-up of 29 months, the median PFS with rituximab and placebo was 22 months, whereas it has not been reached for the investigational arm.
Furthermore, the ORR for patients treated with ibrutinib and rituximab was 92% if one takes into consideration minor responses, as well. Other clinically relevant observations were the abrogation of the IgM flood effect, which we see when patients get only rituximab, the elimination of the rituximab-associated diffusion reactions, and the very significant improvements of the hemoglobin, which occurred in 95% of the patients who were treated.
Furthermore, we know that a minority of patients with Waldenström macroglobulinemia harbor mutations at MYD88 and CXCR4. We know that when these mutations are present, the response rate to ibrutinib is lower and the PFS tends to be shorter. With the combination of ibrutinib and rituximab, we were able to abrogate the adverse effect of these mutations.
We believe now that we have a new standard of care for the treatment of [patients with] this disease and, in the future, we would like to have further improvements. We would like to increase the depths of response; we only had a minority of patients who achieved a very good partial response or complete response. Also, we would like to have regimens that will allow patients to have a treatment-free interval.
I believe that we need to add, in the context of trials, other agents to this backbone of ibrutinib and rituximab, such as venetoclax (Venclexta), bendamustine, or new proteasome inhibitors, such as carfilzomib (Kyprolis), to see whether, with these treatments, we may improve further upon these results.The challenge that they face is that, when they're being treated with BTK inhibitors, this treatment has to be continuous. It is well tolerated, but if treatment stops for more than 1 week, we see that the IgM starts going up. Because these are patients who live for many years, we would like them to have treatment-free intervals, and thus, I believe that by combining BTK inhibitors such as ibrutinib with other regimens, that will allow us to have this approach—triplets that will include a class of agents that have single-agent activity and a different mechanism of action.This is a disease of the elderly. The median age at diagnosis is around 70. First of all, there are many patients being diagnosed by chance. We have to be very careful not to initiate treatment unless there are specific indications—anemia, enlarged lymph nodes, symptoms of weight loss, night fever, a lot of sweating, or a drop in platelet count. There are specific indications to treat this disease.
The other issue is, from the time of initiation of treatment, the expected survival is 10 or 15 years at the median. We have a lot of patients dying of unrelated causes, so it is a disease that can be managed for an extended period of time in the majority of patients.